Evidence map›Paper›PMID 10082559›Full record

ArticleMolecular and cellular biology1999

p70 S6 kinase is regulated by protein kinase Czeta and participates in a phosphoinositide 3-kinase-regulated signalling complex.

A Romanelli, K A Martin, A Toker, J Blenis

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 180 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Sustained PKCβII activity confers oncogenic properties in a phospholipase D- and mTOR-dependent manner.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2014
    Article
  16. Review
  17. Atypical protein kinase C and Par3 are required for proteoglycan-induced axon growth inhibition.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013
    Article
  18. Article
  19. Mammalian TOR signaling to the AGC kinases.Critical reviews in biochemistry and molecular biology · 2011
    Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

A RomanelliDepartment of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.
K A Martin
A Toker
J Blenis
Harvard University · USBoston Biomedical Research Institute · US

Funding

SIGNAL TRANSDUCTION TO PP70 S6KR01GM051405 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI BLENIS, JOHN · 1995 to 2023
$14.0M
Regulation and function of the PKC/PKD signaling pathwayR01CA075134 · NCI · BOSTON BIOMEDICAL RESEARCH INSTITUTE · PI TOKER, ALEX · 1999 to 2008
$2.8M
NCI NIH HHS CA75134NCI NIH HHS R01 CA075134NIGMS NIH HHS GM51405NIGMS NIH HHS R01 GM051405
6 · The paper itself

Abstract

p70 S6 kinase (p70S6K) is an important regulator of cell proliferation. Its activation by growth factor requires phosphorylation by various inputs on multiple sites. Data accumulated thus far support a model whereby p70S6K activation requires sequential phosphorylations at proline-directed residues in the putative autoinhibitory pseudosubstrate domain, as well as threonine 389. Threonine 229, a site in the catalytic loop is phosphorylated by phosphoinositide-dependent kinase 1 (PDK-1). Experimental evidence suggests that p70S6K activation requires a phosphoinositide 3-kinase (PI3-K)-dependent signal(s). However, the intermediates between PI3-K and p70S6K remain unclear. Here, we have identified PI3-K-regulated atypical protein kinase C (PKC) isoform PKCzeta as an upstream regulator of p70S6K. In coexpression experiments, we found that a kinase-inactive PKCzeta mutant antagonized activation of p70S6K by epidermal growth factor, PDK-1, and activated Cdc42 and PI3-K. While overexpression of a constitutively active PKCzeta mutant (myristoylated PKCzeta [myr-PKCzeta]) only modestly activated p70S6K, this mutant cooperated with PDK-1 activation of p70S6K. PDK-1-induced activation of a C-terminal truncation mutant of p70S6K was also enhanced by myr-PKCzeta. Moreover, we have found that p70S6K can associate with both PDK-1 and PKCzeta in vivo in a growth factor-independent manner, while PDK-1 and PKCzeta can also associate with each other, suggesting the existence of a multimeric PI3-K signalling complex. This work provides evidence for a link between a phorbol ester-insensitive PKC isoform and p70S6K. The existence of a PI3-K-dependent signalling complex may enable efficient activation of p70S6K in cells.

Indexed as

3-Phosphoinositide-Dependent Protein KinasesEnzyme ActivationEpidermal Growth FactorIsoenzymesPhosphatidylinositol 3-KinasesProtein BindingProtein Kinase CProtein Kinase C zetaProtein Serine-Threonine KinasesRibosomal Protein S6 KinasesSequence DeletionSignal Transduction3-Phosphoinositide-Dependent Protein KinasesEpidermal Growth FactorIsoenzymesPhosphatidylinositol 3-KinasesProtein Kinase CProtein Kinase C zetaProtein Serine-Threonine KinasesRibosomal Protein S6 Kinases

Identifiers

PMID10082559
PMCPMC84086
OpenAlexW2137427671

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.